Evidence map›Paper›PMID 22693444›Full record

ArticlePLoS pathogens2012

Transmitted/founder and chronic subtype C HIV-1 use CD4 and CCR5 receptors with equal efficiency and are not inhibited by blocking the integrin α4β7.

Nicholas F Parrish, Craig B Wilen, Lauren B Banks, Shilpa S Iyer, Jennifer M Pfaff, Jesus F Salazar-Gonzalez, Maria G Salazar, Julie M Decker, Erica H Parrish, Anna Berg and 20 more

Open access · goldAbstract read
In one paragraph

Article in PLoS pathogens, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 116 papers.

0numbers the graph read from it
0cells of the map it votes in
116citing papers in PubMed
9.1field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

116 citing papers in PubMed, 147 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Trial
  4. Trial
  5. Trial
  6. The immunophenotype and proviral landscape of HIV-infected CD4 T cells during antiretroviral therapy.Proceedings of the National Academy of Sciences of the United States of America · 2026
    Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article

56 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

30 authors at 6 institutions in 2 countries.

Nicholas F ParrishDepartment of Microbiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, United States of America.
Craig B Wilen
Lauren B Banks
Shilpa S Iyer
Jennifer M Pfaff
Jesus F Salazar-Gonzalez
Maria G Salazar
Julie M Decker
Erica H Parrish
Anna Berg
Jennifer Hopper
Bhavna Hora
Amit Kumar
Tatenda Mahlokozera
Sally Yuan
Charl Coleman
Marion Vermeulen
Haitao Ding
Christina Ochsenbauer
John C Tilton
Sallie R Permar
John C Kappes
Michael R Betts
Michael P Busch
Feng Gao
David Montefiori
Barton F Haynes
George M Shaw
Beatrice H Hahn
Robert W Doms
University of Pennsylvania · USDuke University · USUniversity of Alabama at Birmingham · USSouth African National Blood Service · ZABlood Systems Research Institute · USCase Western Reserve University · US

Funding

Virology CoreP30AI027763 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI STEVEN Grant DEEKS · 1988 to 2026
$93.6M
Virology CoreP30AI027767 · NIAID · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI OLAF KUTSCH · 1988 to 2026
$84.1M
Viral and Host Determinants of HIV-1 TransmissionU01AI067854 · NIAID · DUKE UNIVERSITY · PI HAYNES, BARTON F · 2005 to 2005
$14.9M
Novel SIVsmm strains for analysis of mucosal transmission and vaccine protectionP01AI088564 · NIAID · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI SHAW, GEORGE M · 2010 to 2014
$12.7M
TRAINING IN HIV PATHOGENESIST32AI007632 · NIAID · UNIVERSITY OF PENNSYLVANIA · PI Frederic D Bushman, James L. Riley · 2000 to 2026
$10.6M
Modified HIV Evns for structure function & vaccine studiesR37AI045378 · NIAID · UNIVERSITY OF PENNSYLVANIA · PI HOXIE, JAMES A · 2004 to 2013
$5.3M
HIV entry and its inhibitionR01AI040880 · NIAID · UNIVERSITY OF PENNSYLVANIA · PI DOMS, ROBERT W. · 1997 to 2010
$4.2M
Penile transmission and neutralization of pathogenic SIVsmmR01AI094604 · NIAID · UNIVERSITY OF PENNSYLVANIA · PI SHAW, GEORGE M · 2011 to 2015
$3.6M
EVALUATION OF CD4 INDEPENDENT HIV AND SIV ENV PROTEINSR01AI045378 · NIAID · UNIVERSITY OF PENNSYLVANIA · PI HOXIE, JAMES A · 1999 to 2003
$1.8M
NIAID NIH HHS P01 AI088564NIAID NIH HHS P30 AI027763NIAID NIH HHS P30 AI027767NIAID NIH HHS R01 AI040880NIAID NIH HHS R01 AI045378NIAID NIH HHS R01 AI094604NIAID NIH HHS R01 AI40880NIAID NIH HHS R01 AI45378NIAID NIH HHS R37 AI045378NIAID NIH HHS T32 AI007632NIAID NIH HHS U01 AI067854PHS HHS P30 045008
6 · The paper itself

Abstract

Sexual transmission of human immunodeficiency virus type 1 (HIV-1) most often results from productive infection by a single transmitted/founder (T/F) virus, indicating a stringent mucosal bottleneck. Understanding the viral traits that overcome this bottleneck could have important implications for HIV-1 vaccine design and other prevention strategies. Most T/F viruses use CCR5 to infect target cells and some encode envelope glycoproteins (Envs) that contain fewer potential N-linked glycosylation sites and shorter V1/V2 variable loops than Envs from chronic viruses. Moreover, it has been reported that the gp120 subunits of certain transmitted Envs bind to the gut-homing integrin α4β7, possibly enhancing virus entry and cell-to-cell spread. Here we sought to determine whether subtype C T/F viruses, which are responsible for the majority of new HIV-1 infections worldwide, share biological properties that increase their transmission fitness, including preferential α4β7 engagement. Using single genome amplification, we generated panels of both T/F (n = 20) and chronic (n = 20) Env constructs as well as full-length T/F (n = 6) and chronic (n = 4) infectious molecular clones (IMCs). We found that T/F and chronic control Envs were indistinguishable in the efficiency with which they used CD4 and CCR5. Both groups of Envs also exhibited the same CD4+ T cell subset tropism and showed similar sensitivity to neutralization by CD4 binding site (CD4bs) antibodies. Finally, saturating concentrations of anti-α4β7 antibodies failed to inhibit infection and replication of T/F as well as chronic control viruses, although the growth of the tissue culture-adapted strain SF162 was modestly impaired. These results indicate that the population bottleneck associated with mucosal HIV-1 acquisition is not due to the selection of T/F viruses that use α4β7, CD4 or CCR5 more efficiently.

Indexed as

Antibodies, NeutralizingAntibodies, ViralCD4 AntigensCD4-Positive T-LymphocytesCells, CulturedCloning, MolecularHIV-1HIV Envelope Protein gp120HIV InfectionsHost-Pathogen InteractionsHumansIntegrinsMucous MembraneNeutralization TestsReceptors, CCR5Viral TropismAntibodies, NeutralizingAntibodies, ViralCD4 Antigensgp120 protein, Human immunodeficiency virus 1HIV Envelope Protein gp120integrin alpha4beta7IntegrinsReceptors, CCR5

Identifiers

PMID22693444
PMCPMC3364951
OpenAlexW2012816187

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.